Klotho upregulation by rapamycin protects against vascular disease in CKD | Zendy

Takayuki Hamano | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Klotho upregulation by rapamycin protects against vascular disease in CKD

Author(s) -

Takayuki Hamano

Publication year - 2015

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2015.223

Subject(s) - downregulation and upregulation , calcification , klotho , vascular smooth muscle , transdifferentiation , pi3k/akt/mtor pathway , endocrinology , restenosis , medicine , chemistry , microbiology and biotechnology , biology , smooth muscle , signal transduction , kidney , biochemistry , stem cell , gene , stent

Medial arterial calcification involves chondrogenic/osteogenic transdifferentiation of vascular smooth muscle cells (VSMCs). Zhao et al. report that phosphate activates the mammalian target of rapamycin (mTOR) cascade in VSMCs, leading to downregulation of Klotho. Furthermore, rapamycin was shown to halt medial calcification. This effect was blunted in the absence of Klotho. Given the concomitant anti-atherosclerotic effects of the mTOR inhibitor, this agent has clinical potential as an inhibitor of intimal atherosclerosis and medial calcification.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research